# Targeting carboxypeptidase A/B activity with the phosphinic inhibitor C28 reduces the asthmatic response in a mouse model of house dust mite-induced asthma

## TL;DR

A new drug reduces asthma symptoms in mice by inhibiting specific enzymes linked to allergic reactions.

## Contribution

Compound 28, a phosphinic inhibitor, effectively mitigates asthma features in a mouse model by targeting carboxypeptidase A/B activity.

## Key findings

- Compound 28 reduced airway hyperresponsiveness and inflammation in asthmatic mice.
- The drug mitigated airway smooth muscle and goblet cell remodeling.
- Inflammatory gene expression in the lungs was suppressed by compound 28.

## Abstract

Metallo-carboxypeptidases are implicated in several pathological contexts but their role in asthma and their potential as therapeutic targets in asthmatic settings are only partly understood. This study sought to investigate whether inhibition of carboxypeptidase activity of A and B-type could mitigate asthma-like symptoms in a mouse model of allergic airway inflammation.

BALB/c mice were sensitized and challenged with repeated intranasal instillations of 10 µg house dust mite extract. Prior to each instillation, groups of mice received intraperitoneally from 0.2 to 1 mg/kg of compound 28, a phosphinic inhibitor of A/B-type carboxypeptidases. Manifestations of asthma-like features were assessed, including airway hyperresponsiveness, airway inflammation, lung histopathology and inflammatory markers.

Treatment with compound 28 protected against airway hyperresponsiveness and profoundly reduced the house dust mite-induced inflammation both in airways and in lung tissue. Moreover, compound 28 could mitigate airway smooth muscle and goblet cell remodelling as well as inflammatory gene expression in the lungs.

Compound 28 could suppress multiple features of asthma in a physiologically relevant mouse model, reinforcing the potential of targeting A/B type carboxypeptidases for therapeutic purposes in allergic asthma.

The online version contains supplementary material available at 10.1007/s00011-025-02046-z.